Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / COM
-
Number of holders
-
114
-
Total 13F shares, excl. options
-
35,028,415
-
Shares change
-
-3,161,445
-
Total reported value, excl. options
-
$574,817,122
-
Value change
-
-$59,217,704
-
Put/Call ratio
-
232%
-
Number of buys
-
57
-
Number of sells
-
-55
-
Price
-
$16.41
Significant Holders of TCR2 THERAPEUTICS INC - COM (TCRR) as of Q2 2021
142 filings reported holding TCRR - TCR2 THERAPEUTICS INC - COM as of Q2 2021.
TCR2 THERAPEUTICS INC - COM (TCRR) has 114 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 35,028,415 shares
.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (5,334,338 shares), MPM ASSET MANAGEMENT LLC (4,050,865 shares), MPM Oncology Impact Management LP (3,370,982 shares), Redmile Group, LLC (3,235,809 shares), BlackRock Inc. (2,937,026 shares), STATE STREET CORP (2,231,224 shares), VANGUARD GROUP INC (1,389,360 shares), ArrowMark Colorado Holdings LLC (1,027,128 shares), Candriam Luxembourg S.C.A. (934,551 shares), and Artal Group S.A. (750,000 shares).
This table shows the top 114 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.